medigraphic.com
ISSN 1561-3011 (Electronic)

2014, Number 3

<< Back Next >>

Rev Cubana Invest Bioméd 2014; 33 (3)

CD4 + T lymphocytes and viral load in patients with AIDS debut receiving antiretroviral therapy

Hernández RD, Pérez ÁJ, Carr PA

Language: Spanish
References: 29
Page:
PDF size: 399.63 Kb.


ABSTRACT

Introduction: the AIDS premiere is a form of presentation of the illness caused by HIV that is characterized by alteration of the patient's general state, waste syndrome, appearance of serious opportunists infections, neoplasia and neurological alterations.
Methods: the behavior of the CD4+ T lymphocytes levels were studied and of viral load in patient with AIDS premiere and antiretroviral therapy, to the beginning and one year after the treatment. 55 patients those were studied which had to the beginning of the treatment CD4+ T lymphocytes counts less to 200cel/µL and high viral load.
Results: after a year of therapy, the values of CD4+ T cells recovered and the viral load diminished at non detecting levels in the evaluated patients.
Conclusions: the results of this study confirm the benefits of antiretroviral therapy, particularly for patient with AIDS premiere.


REFERENCES

  1. Curran JW, Jafe HW, Ardí AM, Morgan WM, Selik RM, Dondero TJ. Epidemiology of HIV infection and AIDS in the United Status. Science. 2008; 239:610-616.

  2. Kilmarx PH. Global epidemiology of HIV. Curr Opin HIV AIDS. 2011;4:240-246.

  3. Weiss RA. Special anniversary review: twenty-five years of human immunodeficiency virus research: successes and challenges. Clin Exp Immunol. 2008;152:201-210.

  4. Mayer K, Pizer HF, Venkatesh KK. The social ecology of HIV/AIDS. Med Clin North Am. 2008;92:1363-1375.

  5. Oropesa L, Sánchez L, Berdasquera D, Gala A, Pérez J, Lantero MI. Debut clínico de Sida en Cuba. Rev Cubana Med Trop. 2007;59(2):127-133.

  6. Castilla J, Sobrino P, Fuente L, Noguer I, Guerra L, Parras F. Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence. AIDS. 2002;16:1945-1951.

  7. Ochoa R, Rojo N. Investigaciones sobre VIH en el contexto de la salud pública cubana. La Habana: Centro Nacional de Prevención de las ITS-VIH/sida; 2006:15-24.

  8. Esteban RJ. Principios de urgencias, emergencias y cuidados críticos. AIDS. 2004;16:1945-1951.

  9. Klatt EC. Pathology of AIDS. Versión 22. Mercer University School of Medicine, Savannah 2011:44-56.

  10. Catálogo Software Flor Cytometry. Disponible en: http://www.bdbiosciences.com/flowcytometry/. [Consultado: junio 2013].

  11. Catalogo NucliSENS® easyMAG®. URL disponible en: http://www.biomereux.com.ar. [Consultado: junio 2013].

  12. Anuario Estadístico de Salud en Cuba. 2013. Disponible en: http://www.infomed.sld.cu/servicios/estadistica. [Consultado: febrero 2014].

  13. Cansio I, Sánchez J, Reymond V, López VJ. Información Básica sobre la atención integral a personas viviendo con VIH/sida. La Habana: Editorial Lazo Adentro, 2006.

  14. Redi R, Calza L. HIV infection and AIDS in advanced age. Epidemiological and clinical issues, therapeutic and management problems. Infez Med. 2004;12(3):152-73.

  15. Health Protection Agency. HIV in the United Kingdom: 2011 Report. London: Health Protection Services, Colindale. November 2011.

  16. Pérez J, Pérez D, González I, Díaz M, Millán JC, Orta M. Pautas cubanas para el tratamiento antirretroviral en los pacientes con VIH/sida. La Habana, Cuba 2004.

  17. ART Cohort Collaboration. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS. 2007; 21:1185-1197.

  18. World Health Organization. Antiretroviral therapy. 2007. Disponible en: http://www.who.int/hiv/topics/treatment/en. [Consultado: abril, 2013].

  19. Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M. Characteristics, determinans, and clinical relevance of CD4 T cell recovery to < 500 cells/ul in HIV type 1- infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005;41:361-372.

  20. Sasson SC, Kelleher AD, Cooper DA. The modern ART of HIV infection management: towards a tailored approach to maximize CD4 T cell reconstitution. Clin Infect Dis. 2005;41:373-375.

  21. Leth F, Phanuphak P, Ruxrungtham K, Baraldi E, Millar S, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine,efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Rev The Lancet. 2004;363(4):1253-63.

  22. Gwenda V, Mike S, Hermione L, Vas N, Diane MG, Gillian D, Colin B, Ed Wilkins, Sam Walters and Gareth Tudor-Williams. Nevirapine use in HIVinfected children. AIDS. 2003;17(11):1639-1647.

  23. Laurent C, Kouanfack C, Koulla-Shiro S, Nkoué N, Bourgeois A, Calmy A, Lactuock B, et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet. 2004 Jul 3-9;364(9428):29-34.

  24. Amin J, Moore A, Carr A, frec. M. A, Law M, Emery S, cooper D.A et al. Combined Analisis of Two-Year Follow-Up from Two Open-Label Randomized Trials Comparing Efficacy of Three Nucleoside Reverse Transcriptase Inhibitor Backbones for Previously Untreated HIV-1 Infection: Oz Combo 1 and 2. HIV Clin Trials.2003;4 (4):252-261.

  25. Monforte A, Lepri A, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients.I.CO.N.A. Study Group. Italian Cohort of Antiretroviral- Naïve Patients. AIDS 2000;14:499-507.

  26. Dorrucci M, Pezzotti P, Grisorio B, et al. Time to discontinuation of the first highly active antiretroviral therapy regimen: a comparison between protease inhibitor and nonnucleoside reverse transcriptase inhibitor containing regimen. AIDS. 2011;15:1733-36.

  27. MacArthur RD, et.al. Comparison of prognostic significance of latest CD4 cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy. HIV Clin Trials. 2005; 6:127-135.

  28. Ruibal-Brunet I, Cuevas MT, Díaz-Torres H, Villahermosa ML, Noa-Romero E, Vázquez de Parga E, et al. Genotypic resistance mutations to antiretroviral drugs in HIV-1B and non-B subtypes from Cuba. Pam Am J Public Health. 2001;10(39):174-9.

  29. Pérez J, Ortega LM. Pautas para el manejo de la infección por VIH/sida. La Habana: Cuba 2012.




2020     |     www.medigraphic.com